Brind.

Celcuity Inc. and Corcept Therapeutics are noted for developing targeted therapies in the United States.

Steady: 0 in the last 7 days Updated sep 22

The latest in this situation

  1. Corcept Therapeutics is seeking final approval from the European Commission for a cancer therapy already approved in the US market.

How it started

1 report, 1 independent, last reported Jul 31. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Celcuity Inc. and Corcept Therapeutics are noted for developing targeted therapies in the United States.

Who's involved

What this event is mainly about
Corcept Therapeutics

How it developed

Newest first. Tap a step to see who reported it.
  1. Corcept Therapeutics is seeking final approval from the European Commission for a cancer therapy already approved in the US market.Sub-event
  2. Both Celcuity and Corcept are developing targeted therapies in the US.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Simply Wall St.Insiders Favor These 3 High Growth Companies Over the last 7 days, the United States market has remained flat, yet it has seen a 16% increase over the past year with earnings projected to grow by 15%